Erschienen in:
01.12.2021 | Stroke (DL Tirschwell, Section Editor)
Stroke Prevention in Patients with Patent Foramen Ovale
verfasst von:
Alison Thaler, Alexandra Kvernland, Sean Kelly, Christopher Song, Hugo J. Aparicio, Brian Mac Grory, Shadi Yaghi
Erschienen in:
Current Cardiology Reports
|
Ausgabe 12/2021
Einloggen, um Zugang zu erhalten
Abstract
Purpose of Review
Patent foramen ovale (PFO) is widely prevalent and studies have suggested an association with ischemic stroke. In this review, we aim to highlight current management of patients with ischemic stroke in the setting of PFO and discuss some areas of controversy.
Recent Findings
Upon reviewing the literature, we have found that the evidence regarding the management of patients with cryptogenic stroke and PFO has come a long way in the past several years, and many uncertainties remain in clinical practice. The Risk of Paradoxical Embolism (RoPE) score helps to predict the probability of a pathogenic PFO, and recent trial data confirms the benefit of closure in carefully selected patients. The benefit of closure in older patients and in patients with alternate, competing mechanisms is still uncertain, and the long-term risks of closure are not known. Finally, the efficacy of direct oral anticoagulants (DOACs) in this patient population as compared to other medical therapy or mechanical closure has not yet been investigated. Randomized data is needed to help answer these questions.
Summary
PFO closure is a safe and effective strategy in reducing stroke risk in carefully selected patients with cryptogenic stroke in the setting of a PFO. More studies are needed to test optimal medical treatment strategies and the safety and efficacy of PFO closure in patient subgroups not included in prior PFO closure trials.